Free Shipping in the U.S. for orders over $1000.  Shop Now>>

Recombinant CD138 / Syndecan-1 (SDC1) (Plasma Cell Marker) Antibody [SDC1/4378R]

In Stock
Catalog Number Formulation Size Price
6382-RBM3-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$229.00
6382-RBM3-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$519.00
6382-RBM3-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$519.00
Flat Rate Domestic: $75 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes

Summary

CD138, also designated syndecan-1, is a member of the syndecan family of four transmembrane spanning proteins capable of binding to heparan sulfate and chondroitin sulfate molecules. The syndecans main functions are to control cell growth and differentiation as well as to maintain cell adhesion and cell migration. Under normal conditions CD138 ispredominantly expressed on mature plasma cells and early preB-cells, while other haematolymphoid cells are negative. Various types of epithelial cells are also CD138 positive. Squamous epithelial cells show strong membranous and some cytoplasmic staining, except for the mature superficial squamous epithelial cells which are unstained. Mature mesenchymal and neural tissues are not stained. Among haematolymphoid neoplasms, CD138 is expressed in practically all cases of plasma cell malignancies. Among non-haematolymphoid neoplasms the expression of CD138 is found in various types of carcinoma. In the following, the large majority of cases is CD138 positive: skin squamous cell carcinoma and basal cell carcinoma, colorectal adenocarcinoma, cholangiocarcinoma, transitional cell carcinoma, endometrial adenocarcinoma, ductal and lobular breast carcinoma, hepatocellular carcinoma, renal cell carcinoma, and lung adenocarcinoma.CD138 is a very sensitive and specific marker for identification of plasma cells and plasma cell differentiation within haematolymphoid tissues in benign and neoplastic conditions.

Product Properties & Targets

Host
Rabbit
Applications
Species Reactivity
Isotype / Light Chain
IgG / Kappa
Cellular Localization
Extracellular exosome, Membrane, Secreted
Gene Name
Positive Control
Human tonsil or lymph node.
Immunogen
Recombinant fragment (around aa200-300) of human CD138 protein (exact sequence is proprietary)
Alternate Names
Syndecan-1, Heparan Sulfate Proteoglycan Fibroblast Growth Factor Receptor; SDC1; SYND1; Syndecan Proteoglycan 1; Syndecan-1

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
SDC1/4378R
Chromosome Location
2p24.1
Mol. Weight of Antigen
85kDa

Functions

  • Cell surface proteoglycan that bears both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix. Regulates exosome biogenesis in concert with SDCBP and PDCD6IP (PubMed:22660413).

Key References

  • Nunez AL, et.al, Am J Clin Pathol. 2012 Mar;137(3):423-8.
  • O Connell FP, et al. Am J Clin Pathol. 2004; 121:254-63

Storage & Stability

Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “Recombinant CD138 / Syndecan-1 (SDC1) (Plasma Cell Marker) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK